These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19528132)

  • 21. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian optimal interval design for dose finding in drug-combination trials.
    Lin R; Yin G
    Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
    Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
    Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs.
    Chiuzan C; Garrett-Mayer E; Yeatts SD
    Clin Trials; 2015 Feb; 12(1):24-33. PubMed ID: 25349178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
    Diniz MA; Quanlin-Li ; Tighiouart M
    J Biom Biostat; 2017; 8(6):. PubMed ID: 29552377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel model of the continual reassessment method in Phase I trial.
    Zhang W; Lei W; Zhu X
    Sci Rep; 2023 Mar; 13(1):5047. PubMed ID: 36977709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using the time-to-event continual reassessment method in the presence of partial orders.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.
    Iasonos A; Gounder M; Spriggs DR; Gerecitano JF; Hyman DM; Zohar S; O'Quigley J
    Clin Cancer Res; 2012 Oct; 18(19):5179-87. PubMed ID: 22825582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A modified toxicity probability interval method for dose-finding trials.
    Ji Y; Liu P; Li Y; Bekele BN
    Clin Trials; 2010 Dec; 7(6):653-63. PubMed ID: 20935021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specifications of a continual reassessment method design for phase I trials of combined drugs.
    Wages NA; Conaway MR
    Pharm Stat; 2013; 12(4):217-24. PubMed ID: 23729323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.
    Koopmeiners JS; Wey A
    J Biopharm Stat; 2017; 27(6):1028-1042. PubMed ID: 28340333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
    Wages NA; Fadul CE
    Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interplay of priors and skeletons in two-stage continual reassessment method.
    Iasonos A; O'Quigley J
    Stat Med; 2012 Dec; 31(30):4321-36. PubMed ID: 22893483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continual reassessment method with regularization in phase I clinical trials.
    Li X; Ivanova A; Tian H; Lim P; Liu K
    J Biopharm Stat; 2020 Nov; 30(6):964-978. PubMed ID: 32926652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-finding design and benchmark for a right censored endpoint.
    Andrillon A; Chevret S; Lee SM; Biard L
    J Biopharm Stat; 2020 Nov; 30(6):948-963. PubMed ID: 33222634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring late-onset toxicities in phase I trials using predicted risks.
    Bekele BN; Ji Y; Shen Y; Thall PF
    Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.